E1A11; Randomized Phase III Trial of Bortezomib Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib Lenalidomide Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma

Recruitment Status

Open

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Open

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176

E1A11; Randomized Phase III Trial of Bortezomib Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib Lenalidomide Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma

Recruitment Status

Contact the research team to learn more about this study. Fields marked with asterisk (*) are required

Recruitment Status

Volunteer Registry

Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required